The Centers for Medicare and Medicaid Services (CMS) reconsider coverage of GLP-1 receptor agonists for obesity management after previously rescinding a Biden-era proposal. The agency contemplates a five-year pilot allowing state Medicaid and Medicare Part D plans to opt into covering drugs like semaglutide and tirzepatide for weight management. Stakeholders note the potential impact on patient access amid ongoing debates on obesity as a chronic disease and cost-benefit considerations.